Palbociclib Market Size, Share and Industry Analysis with Trends, Forecasts 2019-2025
Palbociclib Market Size, Share and Industry Analysis by Type (Solo Drug, and Combination Therapy), By Applications (Estrogen Receptor Positive (ER+) Breast Cancer, HER2 Negative (HER2-) Advanced Breast Cancer, Metastatic Breast Cancer, Other), By Region (North America, Europe, Asia-Pacific, and Rest of the World), Competitive Market Share & Forecast, 2019 - 2025
The global palbociclib market is expected to reach USD
xxx million by 2025 from USD xxx million in 2018, at a CAGR of xx% during the
forecast period. Global Palbociclib Market report covers market size, market
share and market forecast by product types, gender, regions, and key players,
with historical data along with forecast from 2019 to 2025. The report covers
an in depth description, competitive scenario, wide product portfolio of key
vendors and business strategy adopted by competitors along with their SWOT
analysis, revenue, sales and Porter's Five Forces Analysis.
Palbociclib Market Outlook:
Palbociclib is an innovative drug developed and launched by Pfizer for the treatment of hormonal receptor positive (HR-positive) and human epidermal growth factor-negative (HER2-negative) breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6, and it is a first CDK4/6 inhibitor to be approved for cancer treatment. Though palbociclib is an effective therapeutic alternative and the palbociclib market size is significantly growing each day, it has a few side effects that might affect the patient’s health. The major side effect associated with administration of palbociclib is neutropenia, leukopenia and anemia. These conditions impacts the immune system of the patient, and is thus likely responsible for infections. More than 10% of patients also experience common side effects such as fatigue, nausea, headache, thrombocytopenia, diarrhea, respiratory infection, vomiting, and decreased appetite.
Palbociclib is a drug used for targeted therapy that blocks the growth and spread of cancer. It targets and interfere with processes in the cells that cause cancer to grow. Certain proteins in the human body cause cells to grow and divide. In ER positive (ER+), HER2-negative breast cancer, these proteins become overactive and can stimulate breast cancer cells to grow. Palbociclib works by blocking these proteins, and helps stop the cancer cells to grow and divide. This drug when combined with hormonal therapy, blocks the effect of oestrogen on cancer cells, and helps to delay the growth of ER+, HER2 negative breast cancer. Palbociclib’s ability to reduce the cancer cells and improve patient’s health has improved its adoption, and resulted in increased palbociclib market size.
Palbociclib Market Trends and Advancements:
Palbociclib market is an upcoming industry segment and currently, numerous clinical studies are being conducted to prove additional effects and implications of this drug. Combining palbociclib with current endocrine therapy is one such clinical trial that was conducted and presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. This trial has proven to be effective in the palbociclib market as it improves outcomes among women with hormone receptor positive (HRplus), HER2 negative (HER2-) metastatic breast cancer (MBC) who progress on endocrine therapy (ET). Moreover, palbociclib is also prescribed as a combination therapy to enhance its therapeutic value. When used as primary therapy, palbociclib is mainly given in combination with an aromatase inhibitor such as letrozole. However, in women who have progressed on endocrine-based therapy, it can be given with the oestrogen receptor antagonist fulvestrant. Such combinations and advanced administrations enables in strengthening the power of the drug and helps provide a highly effective therapeutic outcome.
On the basis of its advantages and therapeutic results, researchers are also studying some additional applications and effects of palbociclib on human body. With regards to this, in April 2019 US Food and Drug Administration (FDA) extended the indications of palbociclib in combination with specific endocrine therapies for metastatic breast cancer in male patients. These expanded indications for male patients were approved on the basis of postmarketing reports and electronic health records that showed that the safety profile for men treated with palbociclib was consistent with the safety profile in women treated with palbociclib. These and many such advancements in the palbociclib market are proving to be dynamic and are highly contributing to increase the adoption and applications palbociclib in healthcare industry.
Palbociclib Market Drivers and Restraints:
There are numerous dynamics that have a crucial impact on the growth and development of the global palbociclib market. Primary factor influencing this growth is the increasing prevalence of breast cancer across the globe. According to World Cancer Research Fund and American Institute for Cancer Research, breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. In 2018, over 2 million (i.e. 11.6% of total cancer cases) new breast cancer cases were registered considering both male and female population in the world. The global palbociclib market is highly impacted by this high number of patients suffering with breast cancer. Moreover, rigorous research and development investments, increasing number of product approvals, and growing adoption of palbociclib as a primary line of treatment, are some of the additional factors driving the growth of this market. However, side effects associated with palbociclib are likely to restrain the growth of palbociclib market during the forecast period.
Palbociclib Market Segmentation and Geographic Outlook:
The palbociclib market is segmented on the basis of type, gender, and geography. On the basis of type, the market is segmented into solo drug, and combination therapy. The gender segment is divided into male and female. Geographic breakdown and deep analysis of each of the segments mentioned above is included for North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to dominate the market by holding maximum market share of the global palbociclib market. However, Asia-Pacific is expected to experience a fastest growth during the forecast period. Large number of breast cancer patients in the low income economies are likely to drive the growth of palbociclib market in this region.
Palbociclib Market Competitive Landscape:
As the pharmaceutical industry is rapidly advancing, large number of companies are seeking for new and advanced ways to expand their market presence. Currently, along with Pfizer, Eli Lily and Novartis also provide competitive products in the palbociclib market. These players are significantly improvising their product line by introducing innovative products. Rigorous research and development activities and focus towards product approvals are the major focus of these companies to gain a competitive market share. In addition to product development and launch, geographic expansions is also a primary focus of the companies acting this market.
What you get from the Palbociclib Market Research Report:
- The study provides an in-depth analysis of the palbociclib market with current and future trends to explain the imminent investment pockets in the market
- Current and future trends are outlined to determine the overall attractiveness and to single out profitable trends to gain a stronger foothold in the market
- The report provides information regarding key drivers, restraints and opportunities with impact analysis
- Quantitative analysis of the current market and estimations through 2018-2025 are provided to showcase the financial caliber of the market
- Porters Five Forces model and SWOT analysis of the industry illustrates the potency of the buyers & suppliers participating in the market
- Value chain analysis in the report provides a clear understanding of the roles of stakeholders involved in the value chain
Choose License Type
Why Choose Us
24/5 Research support
Get your queries resolved from an industry expert.
Custom research service
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.